Novartis Quarterly Financial Results

Q3 2018

2018 Q3 results - Thursday, October 18, 2018

Media release

English (PDF 0.1 MB)

Deutsch (PDF 0.1 MB)

Français (PDF 0.2 MB)

 

Interim financial report (PDF 0.7 MB)

Watch the webcast

Read the presentation transcript

Download the podcast (MP3 38 MB)

Download the presentation (PDF 1.8 MB)

 

Key figures1  
  Q3 2018
(USD m)		 Q3 2017
(USD m)		 % change
(USD/cc)
Net sales 12,779 12,413 3 (cc: 6)
Operating income 1,939 2,357 -18 (cc: -13)
Net income 1,624 2,083 -22 (cc: -18)
EPS (USD) 0.70 0.89 -21 (cc: -17)
Free cash flow 3,301 3,064 8

Core		      
Operating income 3,555 3,382 5 (cc: 9)
Net income 3,064 3,017 2 (cc: 5)
EPS (USD) 1.32 1.29 2 (cc: 6)

 

 

 

  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Q2 2018

2018 Q2 results - Wednesday, July 18, 2018

Media release

English (PDF 0.1 MB)

Deutsch (PDF 0.1 MB)

Français (PDF 0.2 MB)

 

Interim financial report (PDF 0.5 MB)

Watch the webcast

Read the presentation transcript

Download the presentation (PDF 1.8 MB)

Download the podcast (MP3 93 MB)

 

Key figures1 Q2 2018
(USD m)		 Q2 2017
(USD m)		 % change
(USD/cc)
Net sales 13,158 12,242 7 (cc: 5)
Operating income 2,484 2,280 9 (cc: 6)
Net income 7,768 1,979 nm (cc: nm)
EPS (USD) 3.34 0.84 nm (cc: nm)
Free cash flow 3,562 3,243 10

Core		      
Operating income 3,541 3,235 9 (cc: 7)
Net income 3,011 2,866 5 (cc: 3)
EPS (USD) 1.29 1.22 6 (cc: 4)
  1. nm = not meaningful
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 54 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Form 6-K Q2 2018

Documents Novartis results in line with requirements of the US Securities and Exchange Commission (SEC).

English (PDF 0.6 MB)

XBRL package Q2 2018

Documents Novartis results in XML format in line with requirements of the US Securities and Exchange Commission (SEC).

XBRL Package (ZIP 0.3 MB)

Q1 2018

2018 Q1 results - Thursday, April 19, 2018

Media release

English (PDF 0.1 MB)

Deutsch (PDF 0.1 MB)

Français (PDF 0.2 MB)

Interim financial report (PDF 0.5 MB)

Watch the webcast

Read the presentation transcript

Download the presentation (PDF 1.6 MB)

Download the podcast (MP3 41 MB)

 

Key figures1 Q1 2018
(USD m)		 Q1 2017
(USD m)		 % change
(USD/cc)
Net sales 12,694 11,539 10 (cc: 4)
Operating income 2,447 1,922 27 (cc: 17)
Net income 2,028 1,665 22 (cc: 12)
EPS (USD) 0.87 0.70 24 (cc: 14)
Free cash flow 1,915 1,665 15

Core		      
Operating income 3,340 3,010 11 (cc: 4)
Net income 2,982 2,690 11 (cc: 4)
EPS (USD) 1.28 1.13 13 (cc: 6)

 

 

 

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 43 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this table refer to same period in prior year.

Annual results and Q4 2017

2017 Q4 and annual results
Wednesday, January 24, 2018

Media release

English (PDF 0.4 MB)

Deutsch (PDF 0.3 MB)

Français (PDF 0.5 MB)

 

Condensed financial report (PDF 0.5 MB)

 

Watch the webcast

Download the presentation (PDF 2.8 MB)

Download the podcast (MP3 40 MB)

 

Key figures1 Q4 2017
(USD m)		 Q4 2016
(USD m)		 % change
(USD/cc)
Net sales 12,915 12,322 5 (cc: 2)
Operating income 2,070 1,455 42 (cc: 41)
Net income 1,976 936 111 (cc: 58)
EPS (USD) 0.85 0.40 113 (cc: 59)
Free cash flow 2,456 2,976 -17

Core		      
Operating income 3,223 3,013 7 (cc: 5)
Net income 2,818 2,658 6 (cc: 4)
EPS (USD) 1.21 1.12 8 (cc: 6)

 

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 42 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Archive

2017 Quarterly Results

2017 Q3 Media Release (PDF 0.1 MB)

2017 Q3 Financial Report (PDF 0.5 MB)

2017 Q2 Media Release (PDF 0.4 MB)

2017 Q2 Financial Report (PDF 0.5 MB)

2017 Q1 Media Release (PDF 0.3 MB)

2017 Q1 Financial Report (PDF 0.4 MB)

2016 Quarterly Results

2016 Q4 Media Release (PDF 0.4 MB)

2016 Q4 Financial Report (PDF 0.5 MB)

2016 Q3 Media Release (PDF 0.1 MB)

2016 Q3 Financial Report (PDF 0.5 MB)

2016 Q2 Media Release (PDF 0.3 MB)

2016 Q2 Financial Report (PDF 0.5 MB)

2016 Q1 Media Release (PDF 0.3 MB)

2016 Q1 Financial Report (PDF 0.4 MB)

2015 Quarterly Results

2015 Q4 Media Release (PDF 0.5 MB)

2015 Q4 Financial Report (PDF 0.6 MB)

2015 Q3 Media Release (PDF 0.5 MB)

2015 Q3 Financial Report (PDF 0.6 MB)

2015 Q2 Media Release (PDF 0.4 MB)

2015 Q2 Financial Report (PDF 0.6 MB)

2015 Q1 Media Release (PDF 0.4 MB)

2015 Q1 Financial Report (PDF 0.5 MB)

2014 Quarterly Results

2014 Q4 Media Release (PDF 0.5 MB)

2014 Q4 Financial Report (PDF 0.6 MB)

2014 Q3 Media Release (PDF 0.5 MB)

2014 Q3 Financial Report (PDF 0.6 MB)

2014 Q2 Media Release (PDF 0.5 MB)

2014 Q2 Financial Report (PDF 0.6 MB)

2014 Q1 Media Release (PDF 0.3 MB)

2014 Q1 Financial Report (PDF 0.3 MB)

2013 Quarterly Results

2013 Q4 Media Release (PDF 0.4 MB)

2013 Q4 Financial Report (PDF 0.4 MB)

2013 Q3 Media Release (PDF 0.4 MB)

2013 Q3 Financial Report (PDF 0.4 MB)

2013 Q2 Media Release (PDF 0.4 MB)

2013 Q2 Financial Report (PDF 0.4 MB)

2013 Q1 Media Release (PDF 0.4 MB)

2013 Q1 Financial Report (PDF 0.3 MB)

Disclaimer: 

Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

Related Links

Presentations and Events

View recent presentations and learn more about upcoming events

Visit our Event Calendar
 

Contact Investor Relations

Investors International:
Call +41 61 324 79 44

Investors North America:
Call +1 212 830 24 48

Novartis Share Registry:
For information relating to the registration of your shares, including name or address changes, please contact us by e‑mail or telephone:
Call +41 61 324 72 04